Coronavirus Update: Veklury Shows Mortality Benefit In Real-World Data Analyses
Vir/GSK Announce Positive Phase III Data For Sotrovimab
Sotrovimab data could help with uptake, though the market remains challenging as infections fall. Plus RedHill presents encouraging Phase II data for oral drug to treat COVID-19 infection and inflammation after completing Phase II/III study enrollment and Japan taps its world-leading supercomputer.
You may also be interested in...
Roche and Eli Lilly’s monoclonal antibody cocktails seem to show reduced efficacy against the Delta Plus variant, first identified in Europe, but more evidence might be needed to support the finding. Meanwhile, GSK’s Indian unit is gearing up to submit an application for accelerated approval of sotrovimab.
The green light for the COVID-19 antibody therapy is welcome news for the partners, but rising vaccination rates plus three other competitors in Europe will limit revenues.
Descovy saw a sales decline, though that was due to payer discounts for PrEP, with the drug’s market share continuing to grow.